← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Vivo Opportunity Cayman Fund, L.P.
10% Owner
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001875722
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 3
- Purchases · 24M
- 3
- Average purchase
- $144.5K
- Median purchase
- $31.8K
- Gross purchase value
- $433.5K
Companies: InMed Pharmaceuticals Inc.
3 SEC accession(s) · 3 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-16 | InMed Pharmaceuticals Inc. | INM | 10% Owner | $31.8K | Open filing |
| 2026-07-02 | InMed Pharmaceuticals Inc. | INM | 10% Owner | $10.1K | Open filing |
| 2026-06-10 | InMed Pharmaceuticals Inc. | INM | 10% Owner | $391.6K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 1/3
- Large purchase ≥ $100k
- 1/3
- Cluster buying · 15D
- 3/3
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.